Pfizer’s Own Study Confirms Paxlovid Sucks

Pfizer’s Own Study Confirms Paxlovid Sucks

A Pfizer-funded, peer-reviewed paper authored by Pfizer scientists reveals that the company’s antiviral COVID medication Paxlovid completely sucks, confirming what everyone’s known since it came out.

In a randomized phase 2-3 trial of the drug conducted between Aug. 25, 2021 through July 25, 2022, 654 out of 1,296 patients were dosed with at least one 300mg dose of Paxlovid + 100mg of protease inhibitor ritonavir vs. a placebo group. The results showed that the median time until COVID-19 symptoms ended through day 28 was 12 days in the treatment group vs. 13 days in the placebo group.

According to the authors, the result of the drug, which is also known as nirmatrelvir, “was not significant.”

“Similar results were observed in the high-risk subgroup (i.e., participants who had been vaccinated and had at least one risk factor for severe illness) and in the standard-risk subgroup (i.e., those who had no risk factors for severe illness and had never been vaccinated or had not been vaccinated within the previous 12 months),” the authors added.

And while 0.8% of the Paxlovid group suffered ‘hospitalization or death’ vs. 1.6% of placebo recipients, the authors also concluded that it was not statistically significant, however placebo recipients had longer average hospital stays and were more likely to be admitted to intensive care units.

According to the authors, “the usefulness of nirmatrelvir–ritonavir in patients who are not at high risk for severe COVID-19 has not been established.“

The trial included adults who had tested positive for COVID-19 and shown at least one symptom, had previously received the COVID-19 vaccine, and had at least one risk factor – such as being a cigarette smoker.

Pfizer had previously

Continue reading Pfizer's Own Study Confirms Paxlovid Sucks at ZeroHedge.